<DOC>
	<DOCNO>NCT01400555</DOCNO>
	<brief_summary>The purpose study evaluate maximum safe dose abiraterone acetate administer combination docetaxel plus prednisone patient metastatic castration-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>A Safety Study Abiraterone Acetate Administered Combination With Docetaxel Patients With Metastatic Castration-Resistant Prostate Cancer ( mCRPC )</brief_title>
	<detailed_description>This open-label ( patient doctor know identity study drug administer ) , uncontrolled ( patient assign treatment chance ) , multicenter safety study escalate dose level abiraterone acetate administer combination docetaxel plus prednisone patient metastatic castration-resistant prostate cancer ( mCRPC ) . This study conduct 2 part . Part I consist Screening , Treatment , assessment dose-limiting toxicity ( DLT ) , determination maximum tolerate dose ( MTD ) . Participants enrol sequential 6-subject cohort ( group ) administer combination therapy ( abiraterone acetate docetaxel plus prednisone ) accord dose-escalation schedule . The abiraterone acetate dose study escalate 500 mg 1000 mg daily MTD determine . The MTD high combination dose among dose combination investigate study 2 ( 33 % ) patient cohort experience DLT . A DLT define adverse event occur Day 1 Week 2 ( first dose abiraterone acetate ) day Day 1 Week 7 docetaxel infusion ( 3 week second docetaxel infusion ) ; non-hematological toxicity &gt; =Grade 3 ; Grade 4 neutropenia last 5 day , neutropenia complicate fever , systemic infection ; thrombocytopenia &lt; 25,000/mcL , thrombocytopenia require platelet transfusion ; , subjectively intolerable toxicity . Part II study consist Continuing Treatment , patient remain allocated dose level , escalate combination MTD , discontinuation docetaxel ( toxicity intolerability develop ) continue abiraterone acetate ( 1000 mg/day ) plus prednisone , disease progression ; End Treatment , posttreatment efficacy safety document ; Follow-Up , survival status new antitumor therapy monitor . Blood sample pharmacokinetic efficacy measurement collect select time study . Safety monitor . The total duration study participation may 36 month . Oral abiraterone acetate administer single daily dose ( 500 , 750 , 1000 mg ) . Docetaxel administer every 3 week intravenous ( IV ) infusion ( 60 75 mg/m2 ) 1 hour . Study participant premedicate oral dexamethasone 8 mg 1 , 3 , 12 hour start docetaxel IV infusion . Oral prednisone 5 mg administer twice daily .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Adenocarcinoma prostate Metastatic disease document bone , compute tomography ( CT ) , magnetic resonance image ( MRI ) scan Surgical medical castration testosterone less 50 ng/dL Prostate cancer progression document 1 following : PSA progression accord Prostate Cancer Working Group 2 ( PCWG2 ) criterion , radiographic progression modify Response Evaluation Criteria Solid Tumors ( RECIST ) bone scan Absolute neutrophil count &gt; 1,500 cells/mm3 Platelets &gt; 100,000/Âµl Hemoglobin &gt; =10.0 g/dL Eastern Cooperative Group ( ECOG ) status score &lt; =2 . Elevated liver function test ( LFTs ) : Serum bilirubin &gt; upper limit normal ( ULN ) , alanine ( ALT ) aspartate ( AST ) aminotransferase &gt; 1.5 ULN concomitant alkaline phosphatase &gt; 2.5 ULN Small cell carcinoma prostate Pulmonary brain metastasis , liver metastasis allow LFTs elevate Preexisting neuropathy severe fluid retention Prior cytotoxic chemotherapy metastatic prostate cancer Prior therapy CYP17 inhibitor ( ) investigational agent ( ) target androgen receptor metastatic prostate cancer Treatment primary tumor within 4 week Day 1 Week 1 surgery , radiation , chemotherapy immunotherapy Use investigational drug within 4 week Day 1 Week 1 current enrollment investigational drug device study Prior ketoconazole prostate cancer Recent history ischemic heart disease , electrocardiogram ( ECG ) abnormality , atrial fibrillation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Metastatic Castration-Resistant Prostate Cancer</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>